Archivi tag: AOU Novara – clinical trials

SQUINT

(SQUAMOUS IMMUNOTHERAPY NIVOLUMAB-IPILIMUMAB TRIAL)
AN OPEN LABEL, RANDOMIZED, PHASE II TRIAL OF NIVOLUMAB PLUS IPILIMUMAB VERSUS PLATINUM-BASED CHEMOTHERAPY IN CHEMO-NAIVE METASTATIC OR RECURRENT SQUAMOUS-CELL LUNG CANCER (SQLC)

STADIO
IIIB/IV o recidivato

Il protocollo è attivo nei seguenti centri

Scopri











R2810-ONC-16113

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), IPILIMUMAB (ANTI-CTLA-4 ANTIBODY), AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 <50%

STADIO
IIIB/IV

Il protocollo è attivo nei seguenti centri

Scopri






BEVERLY

STUDY COMPARING BEVACIZUMAB + ERLOTINIB VS ERLOTINIB ALONE AS FIRST LINE TREATMENT OF PATIENTS WITH EGFR MUTATED ADVANCED NON SQUAMOUS NON SMALL CELL LUNG CANCER

Il protocollo è attivo nei seguenti centri

Scopri



















ADAURA

A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTI-CENTRE, STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291 VERSUS PLACEBO, IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CARCINOMA, FOLLOWING COMPLETE TUMOUR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY 

STADIO
IB-IIIA

Il protocollo è attivo nei seguenti centri

Scopri